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Background: Epidermal growth-factor receptor (EGFR) testing
and first-line therapy with gefitinib is becoming the standard
treatment for advanced non-small-cell lung cancer (NSCLC). Yet,
to date, no study has quantified the cost-effectiveness of this
approach within an Asian population, where the prevalence of
activating mutations is higher than among western populations.
Methods: A decision-analytic model was developed to deter-
mine the cost-effectiveness of EGFR testing and first-line treat-
ment with gefitinib for patients with activating EGFR mutations,
versus standard care, which includes first-line treatment with
chemotherapy followed by gefitinib as second-line treatment.
The model uses clinical and outcomes data from three random-
ised clinical trials, and societal (non-subsidised) costs from three
cancer treatment centres in Singapore. Health effects were
expressed as quality-adjusted life-years (QALY) gained. Costs
include relevant costs for prescription medications, physician vis-
its, laboratory tests, scans, hospitalisations, and treatment of
adverse events. All costs and cost-effectiveness ratios were
expressed in 2010 Singapore dollars. Sensitivity analyses were
done to identify the extent to which results were robust to key
model assumptions.
Findings: EGFR testing and first-line treatment with gefitinib
was found to be a dominant strategy (lower costs and greater
effectiveness) compared with standard care. Because the primary
savings in the testing group did not result from not providing
gefitinib to patients who do not benefit, this finding holds regard-
less of the percentage of patients who test positive for EGFR
mutation. In a secondary analysis, first-line treatment with gefiti-
nib was also dominant compared with first-line chemotherapy in
patients with activating EGFR mutations.
Interpretation: Based on these data, EGFR testing and first-line
treatment with gefitinib for patients with activating mutations
should become a standard treatment in advanced NSLC.
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Background: Neuroblastoma is the most common extracranial
tumour, accounting for 8–10% of childhood malignancies and
15% of deaths from cancer in the paediatric age group. Approxi-
mately half of newly diagnosed children are at high risk for
treatment failure. The aim of this study was to evaluate the
response rate of salvage chemotherapy with ifosfamide, carbo-
platin, and etoposide (ICE) when given to previously treated
patients with primary refractory or progressive high-risk
neuroblastoma.
Methods: Sixty-six patients from NCI and CCHE received sal-
vage chemotherapy (ICE) for primary resistance (n = 51, 77.2%)
or disease progression on primary chemotherapy (n = 15 22.8%).
Forty male patients (60.6%) and 26 females (39.4%), between 3
months and 12.5 years of age, were included.
Findings: The most common tumour site was suprarenal, fol-
lowed by retroperitoneal mass. Two patients (3%) died from che-
motherapy toxicity during ICE administration. Evaluation of
tumour response in the remaining 64 patients showed the follow-
ing: complete or partial response in 24 patients (36.5%), stable
disease in 11 patients (16.6%), and progressive disease in 29
patients (43.9%). 14 patients (21.2%) were considered eligible for
an autologous bone-marrow transplant, and 50 patients (78.8%)
failed second-line (salvage) chemotherapy and had palliative
lines of therapy. By the end of the study (May 2010), 47 of 66
(71.2%) of patients were still alive, and 19 of 66 (28.8%) were dead.
Two of 14 patients (14.2%) who underwent haematopoietic stem-
cell transplantation died from post-transplantation disease pro-
gression, and 12 of 14 (85.8%) were in complete cytogenic remis-
sion (CCR).
Interpretation: Chemotherapy with ICE for primary resistant or
progressive stage III–IV neuroblastoma seemswell tolerated. With
a 36.6% response rate, 18% CCR, and 3.0% treatment mortality
rate, it can be considered a good salvage therapy for patients in
whom palliation is appropriate.
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Background: The aim of this study was to compare oestrogen-
receptor (ER) and progesterone-receptor (PgR) status of operable
breast cancers in Vietnamese and Swedish patients.
Methods: Primary breast-cancer tissues were randomly
selected from 249 Vietnamese patients treated in Hanoi, Vietnam,
and 1257 Swedish patients treated in Stockholm, Sweden,
between 2002 and 2003. Clinical information was available for
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all patients in the study. For tumours from Vietnamese patients,
hormone-receptor status was analysed by immunohistochemis-
try, using an automated slide stainer (Bench MarkXT, Ventana)
in combination with anti-ER (SP1 250) and anti-PgR (clone 1E2)
rabbit monoclonal antibodies. Tumours with 10% or more stained
nuclei were considered receptor positive. Tumours from Swedish
patients were analysed with an enzyme immunoassay, with a
cut-off point of 0.10 fmol/lg DNA as positive. The hormone-
receptor frequencies between populations were compared
according to clinicopathologic features.
Findings: Compared with Swedish patients with similar meno-
pausal status, the ER-positive rate was higher in premenopausal
Vietnamese patients (71% vs. 58%, p = 0.007) and lower in post-
menopausal Vietnamese patients (45% vs. 72%, p < 0.001). PgR-
positive tumours were found in 58% of premenopausal and 25%
of postmenopausal Vietnamese patients. The corresponding fig-
ures for Swedish patients were 73% and 66%, respectively.
Interpretation: ER positivity in Vietnamese patients decreased
gradually with rising patient age, by contrast with the trend
observed for Swedish patients, who showed a gradual increase
with age. PgR positivity was lower for Vietnamese than for Swed-
ish patients, regardless of age or menopausal status. Our findings
suggest that a high percentage of young patients could benefit
from endocrine therapy, and indicate a limited benefit among
postmenopausal Vietnamese patients.
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Background: SPARC-like protein 1 (SPARCL1) is an extracelluar
matrix glycoprotein involved in many physiological functions.
Studies have shown an important role for SPARCL1 in cancer
development and progression.
Methods: Tissue microarray blocks were constructed based on
1072 Chinese patients, containing gastric-cancer tissue and adja-
cent normal-mucosa tissue. We analysed expression of SPARCL1
from mRNA and at the protein level, using real-time quantitative
polymerase chain reaction (qRT-PCR), semi-quantitative PCR,
immunohistochemistry (IHC), and Western blotting. We analysed
loss of heterozygosity at the SPARCL1 gene locus, using ten
tumour and matched normal-tissue pairs.
Findings: SPARCL1 mRNA was substantially lower in tumour
specimens than in normal tissues. Down-regulation of SPARCL1
protein was detected in 413 (38.7%) of 1072 primary gastric-
tumour tissues. Significant differences in expression were found
according to histological type, tumour size, depth of invasion,
regional lymph-node involvement, TNM stage, and differentia-
tion. Low expression of SPARCL1 was more common in poorly dif-
ferentiated and undifferentiated tumour tissues (51.1%) than in
well and moderately differentiated tumours (29.9%). Kaplan–
Meier survival curves showed that SPARCL1-positive patients
had longer median survival than SPARCL1-negative patients (59
months vs. 28 months, p = 0.001). Our data also showed signifi-
cantly lower 5-year survival for patients with reduced expression
of SPARCL1 (37.8%) than for patients with high expression (49.7%;
p < 0.001). The incidence of loss of heterozygosity for each indi-
vidual marker was 12.5% (1 of 8) for D4S2462, 20% (2 of 10) for
D4S2929 and 33.3% (3 of 9) for SPARCL1.
Interpretation: Our study revealed the clinical significance of
SPARCL1 expression, providing a basis for a novel negative bio-
marker in gastric-cancer progression and prognosis. Further-
more, SPARCL1 protein might be considered a potential
differentiation marker.
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Background: We did a multi-institutional propensity-matched
study comparing video-assisted thoracic surgery (VATS) with
1 These authors contributed equally.
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